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Background: There is much evidence that smoking cessation interventions are both clinically and cost effective
but these results relate only to the specific study populations involved in the studies. The present study aimed to
compare and contrast results obtained when the effects of smoking cessation are modelled for several different
European countries.
Methods: Local investigators collected data relating to several smoking related diseases. Costs and disease rates
were then modelled up to 2030 for reductions in smoking of 3%, 15% and 30% using an epidemiological
modelling tool, PREVENT.
Results: Models could not be constructed for some countries due to lack of data while for others substantial
amounts of data had to be imputed. In all cases, disease rates fall when smoking cessation occurs. Overall costs
initially fall before eventually rising as lives are saved and the population ages, leading to negative savings in some
cases by the end of the modelled period. The speed and magnitude with which these effects occur are diverse for
different countries.
Conclusions: Health and economic results for different countries vary significantly for the same reductions in
smoking. This suggests that it may be inappropriate to assume that evidence from one country will produce similar
health and economic effects if the same levels of smoking cessation were achieved in another country which has
evident messages for health policy. Problems with obtaining data also highlight the difficulties associated with
modelling such scenarios and underline the need for relevant data to be routinely collected in all countries.
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Evidence based medicine is now an established paradigm
within health care [1]. Growing recognition that resources
for health care are scarce has led to broad acceptance that
the evidence base should include economic as well as clin-
ical evidence. In the UK this is reflected in the work of
the National Institute for Health and Clinical Excellence
(NICE) whose national guidance on health care for England
and Wales is explicitly informed by evidence of cost effect-
iveness as well as clinical effectiveness [2].
Smoking cessation is one aspect of health policy where
the evidence of both clinical and cost effectiveness is
strong [3-6]. The empirical studies which provide this evi-
dence, however, reflect the way that smokers responded to* Correspondence: dcohen@glam.ac.uk
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reproduction in any medium, provided the orsmoking cessation interventions in the countries where
the studies took place. Clearly, cultural and other differ-
ences mean that it cannot be assumed that smokers in
other countries will necessarily respond in exactly the
same way as they did in the countries of observation.
There is thus a potential to misinform if evidence from
one country is used to inform policy in another.
Similarly, estimates of the long term health and eco-
nomic effects which result from reduced smoking are
normally derived from mathematical models populated
with data from the countries where the modelling exer-
cises took place. These results could also potentially mis-
inform health policy in other countries which may have
different rates of smoking prevalence, incidence of
smoking related diseases, mortality from those diseases,
health service costs, etc.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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identify which of 29 European countries participating in the
PESCE project (General Practitioners and the Economics of
Smoking Cessation in Europe), could provide sufficient data
to populate an epidemiological model (PREVENT [7])
which could be used to predict the health and health ser-
vice cost effects of reduced smoking in those countries.
The aim of the study was to predict the effects of a given
reduction in smoking on smoking related disease inci-
dence, mortality and health service costs in each of 29
European countries which could provide sufficient data to
allow the PREVENT model to be run for that country and
to consider the implications for national policies in the
light of differences in results between countries.
This article reports on the findings from the analysis,
describing the effects that have been observed and
recommendations are made for how future analysis can
be improved.
Methods
Identifying achievable reductions in smoking
A range of potentially achievable smoking reductions
was selected from a recent study commissioned by the
UK National Institute for Health and Clinical Excellence
[8]. This study reviewed the UK literature on smoking
cessation interventions delivered by the National Health
Service (NHS), in the workplace and by mass media, and
developed a model to assess their cost effectiveness. This
approach has an advantage over direct comparisons of
cost effectiveness from published studies as the methods
employed in the individual evaluations inevitably vary.
Instead, the review team applied a consistent method-
ology using data extracted from the studies in the review.
This involved modelling a hypothetical cohort of 1000
smokers using the costs and cessation effects reported for
each intervention together with consistently applied data
on mortality by age, gender and smoking status, costs of
smoking related diseases and the utilities (health related
quality of life) associated with each disease. The resulting
cost effectiveness ratios could thus be directly compared
as differences would be due solely to differences in costs
and effects rather than inconsistent evaluation methods.
Table 1 shows the results for the least and most effective
smoking cessation interventions included in the NICE
exercise together with a mid-range intervention. Al-
though different rates of reduction in smoking might be
seen in other countries, these 3 rates (3%, 15% and 35%)
were selected for the present exercise only to illustrate
low, medium and high effects from smoking cessation
interventions. They are of increasing intensity and in-
creasing effectiveness in terms of reductions in smoking
as compared with ‘no intervention’ in each case. All
demonstrate dominance over ‘no intervention’ meaning
that each is both more effective and less costly thandoing nothing and hence is unambiguously more cost
effective than doing nothing.
The PREVENT model
PREVENT is a Public Health model that links changes in
risk factor exposure to changes in risk factor related dis-
ease specific outcomes and to changes in generic health
outcomes [7]. Despite its venerable age, PREVENT is still
being developed. Recently, the central algorithm that re-
lates risk factor change to disease incidence change was
modified from an age group perspective to a cohort per-
spective. This latest version of the PREVENT model
was used to estimate reductions in incidence, mortality
and health service costs of 4 smoking related diseases
(lung cancer, coronary heart disease (CHD), chronic ob-
structive pulmonary disease (COPD) and stroke) and
health service costs.
The model was initially run for the UK where it was
known that data were available and of good quality.
These data, however, were not always available in the
precise format required for the model. Statistical sources
were used for data on population, live births, net migra-
tion, trends in smoking prevalence, total mortality, dis-
ease specific incidence, prevalence and mortality and
total health service costs. Published studies were used
for disease specific costs for lung cancer [9], COPD [10],
CHD and stroke [11] and for relative risks for lung can-
cer and CHD [12], COPD [13] and stroke [14].
Data for the other European countries were collected
using local investigators who were charged with identify-
ing what data were available in that country. A common
pro-forma was used by each local investigator to ensure
that the same data were provided using common defini-
tions. As this task involved considerable effort and com-
mitment on the part of the local investigators, the quantity
and quality of the data provided would inevitably be
dependent at least to a degree on the time and effort that
each was willing and able to devote to this task.
Where datasets were incomplete, Netherlands data were
often used a basis for estimating proportions of data for
other countries. The Netherlands was chosen for imput-
ation purposes as the data supplied for that country were
of higher quality than others in terms of providing what
the PREVENT model requires. For example, while overall
birth rate figures could have been obtained from publicly
available datasets for countries that did not supply them,
the birth rate input also required a breakdown according
to different age groups, necessitating imputations that
could only be taken from another country where these
had been reported.
Additionally, if the incidence of a disease was not
known but the prevalence was known, the ratio of inci-
dence to prevalence for the Netherlands was used to es-
timate the unknown incidence. PREVENT requires these
Table 1 Summary results of cost effectiveness of 3 smoking cessation interventions






Brief Intervention (BA) 3% 3 minutes of GP time - £12 0.01 Dom
(***)
BA + self help material + NRT (****) +
specialist clinic
15% 4 mins GP time + self help material + NRT + clinic
costs
- £115 0.15 Dom
Nicotine patch + pharmacist +
behavioural programme
35% NRT for 5 weeks + 5 pharmacist consultations + 5
behavioural clinic visits
- £222 0.30 Dom
Source: adapted from [8].
(*) QALY = Quality Adjusted Life Year: a measure capturing both length of life and health state preference adjusted quality of life.
(**) ICER = Incremental Cost Effectiveness Ratio: shows the extra cost of producing one extra QALY for this intervention as compared with no intervention.
(***) Dom = Dominant: A dominant result occurs when the net cost of the intervention is both lower than that of the comparator (in this case no intervention)
and also produces more output (QALYs). A dominant result is unambiguously more cost effective.
(****) Nicotine Replacement Therapy.
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were provided, the age/gender breakdowns were similarly
estimated based on Netherlands data. Where age but not
gender breakdowns were supplied, quantities were split
equally between male and female. Where only total health
service cost figures were supplied, Netherlands rates were
used to estimate age and gender breakdowns for total
costs and individual disease costs. Netherlands cost data
were imputed where total costs figures from individual
countries were not provided.
The DISMOD2 model [15] was used to ensure that fig-
ures for each dataset were internally consistent. DISMOD2
is a software tool provided by the World Health Organisa-
tion that checks the internal consistency of epidemiological
estimates of incidence, prevalence, duration, remission and
case fatality for diseases. It requires a minimum of three in-
put variables to be supplied. A remission rate of 0 is input
to produce estimates for the datasets when fewer than three
of the other variables have available data. For some coun-
tries, DISMOD2 estimated figures that were previously un-
known, while for others, the figures were altered to ensure
that internal consistency was valid.
The main study was undertaken prior to 2010 and
based on availability of data, the base year in all cases
was 2005. Results show the annual predicted reductions
for the years 2010, 2020 and 2030 with reduced smoking
in 2005, as compared with its predictions for those years
without. Figures represent absolute values for each
reported year and are not adjusted for population size.
Ratios of predicted values in 2030 to those in 2010 show
differences in the timing of effects between countries. All
cost data were provided in Euros apart from Switzerland
and the UK where conversions at 1 franc = €0.62 and £1 =
€1.34were used (exchange rates on August 1, 2007). All
costs are in 2005 prices.
Results
Despite the relatively good availability of data for the UK a
number of assumptions were still required. These were
due in large part to the fact that the UK is made up of 4countries; England, Wales, Scotland and Northern Ireland.
While the model required data for the UK, some data
were available only for Great Britain (England, Scotland
and Wales), others for “England and Wales” and others
still for each country individually. An additional file
(‘Additional file 1’) provides a description of the as-
sumptions that were made when these were necessary
and indicate that even for a country with relatively good
data, estimates from modelling exercises need to be
interpreted with a degree of caution due to the large
number of assumptions required.
In addition to the UK, sufficient data were provided to
run the PREVENT model for 9 other European countries
although adjustments and/or imputations were required in
all cases. Results for these countries need to be interpreted
with caution as some imputations required strong assump-
tions. ‘Additional file 2’ reports on how the datasets for
each country were completed. For all other countries use
of the model was judged to be inappropriate as the extent
of missing data was excessive.
Results relating to annual reductions in incidence, mor-
tality and costs of the 4 smoking related diseases are
summarised in Table 2. All countries show important re-
ductions in health service costs as well as incidence and
mortality for the four diseases combined. Orders of mag-
nitude vary considerably as anticipated due inter alia to
differences in population size. However, relationships not
directly related to population such as that between a
country’s long term and short term effects also vary con-
siderably. For example, predicted reductions in disease in-
cidence in 2030 in France and Germany are more than
treble those in 2010 while for the UK and Poland they are
less than double. Similarly the relationship between each
country’s reductions in incidence and savings in health
service costs also vary widely. For example, the predicted
reduction in incidence in 2030 for Poland is roughly twice
that for France (1,971 versus 929 cases) while the cost sav-
ings are similar (€43,154 versus €44,981).
Reported results relate to annual reductions but these
effects are clearly cumulative. By 2030, a 3% reduction in
Table 2 Predicted annual reductions in incidence, mortality and health service savings (€000) of 4 diseases due to
reductions of 3%, 15%, 35% in smoking; Base year = 2005
3% Reduction in smoking 15% Reduction in smoking 35% Reduction in smoking
2010 2020 2030 2010 2020 2030 2010 2020 2030
Netherlands
Incidence 342 590 759 1709 2951 3802 3989 6894 8914
Mortality 38 210 329 184 1044 1653 429 2438 3872
Saving (€000) 2069 10147 16342 10344 50754 81884 24138 118458 191712
Austria
Incidence 412 446 497 2066 2241 2497 4839 5276 5896
Mortality 15 71 107 76 354 545 174 829 1282
Saving (€000) 3025 10273 14620 15131 51540 73517 35342 120948 173168
France
Incidence 298 684 929 1494 3412 4649 3484 7931 10868
Mortality 63 415 616 318 2067 3079 738 4800 7199
Saving (€000) 4729 24193 44981 23949 120864 224911 55855 281527 524636
Germany
Incidence 602 1681 2333 3005 8401 11695 7008 19571 27403
Mortality 156 898 1364 770 4488 6835 1791 10455 16013
Saving (€000) 1133 5110 9378 5667 25539 46951 13214 59503 109802
Ireland
Incidence 68 132 186 339 659 943 790 1537 2207
Mortality 9 45 74 39 222 377 89 520 881
Saving(€000) 410 2405 4647 2047 12031 23295 4780 28095 54563
Poland
Incidence 1069 1626 1971 5359 8129 9899 12509 18982 23252
Mortality 122 552 764 609 2769 3835 1419 6468 9011
Saving (€000) 5734 27445 43154 28683 137299 216436 66975 320545 507479
Portugal
Incidence 99 214 297 502 1067 1494 1174 2487 3497
Mortality 10 55 90 50 262 459 117 615 1074
Saving (€000) 597 4592 8960 2995 22931 44852 6981 53367 104799
Romania
Incidence 656 799 848 3282 4005 4238 7666 9364 9926
Mortality 7 40 73 41 198 366 98 462 859
Saving (€000) 779 2546 3876 3894 12821 19395 9090 29941 45350
Switzerland
Incidence 28 56 47 139 276 228 327 639 532
Mortality 2 8 14 9 49 71 23 113 166
Saving (€000) 296 2414 3281 1479 12023 16417 3444 27810 38391
UK
Incidence 1218 1799 2237 6091 9013 11220 14218 21058 26330
Mortality 264 960 1369 1328 4806 6883 3100 11288 16175
Saving (€000) 9865 30532 40528 49280 152744 203185 115008 356837 476219
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Table 3 Predicted savings in overall health service costs
from reductions of 3%, 15% and 35% in number of
smokers (€000)
2010 2015 2020 2025 2030
3% Reduction in Smoking
Romania 772 1873 2459 3086 3556
Switzerland 286 1225 2181 2804 2667
Portugal 533 1732 2820 3359 2433
Austria 2877 5784 6741 6157 4372
Netherlands 1760 3568 3161 459 −5876
United Kingdom 8512 13213 10788 1636 −14791
Ireland 325 584 345 −431 −2060
Poland 4607 5812 −6950 −33186 −72598
Germany 247 −4535 −16373 −36539 −63056
France 3350 −6110 −45580 −124140 −232400
15% Reduction in Smoking
Romania 3863 9368 12303 15445 17804
Switzerland 1431 6098 10874 14026 13357
Portugal 2664 8649 14081 16801 12203
Austria 14393 28996 33863 31031 22163
Netherlands 8802 17835 15803 2312 −29406
United Kingdom 42566 66987 53975 8239 −74105
Ireland 1624 2919 1727 −2155 −10327
Poland 23045 29059 −34866 −166316 −364111
Germany 1231 −22667 −81771 −182576 −315440
France 16760 −30010 −226010 −618570 −1161660
35% Reduction in Smoking
Romania 9020 21877 28732 36091 41638
Switzerland 3336 14083 25183 32745 31270
Portugal 6212 20123 32756 39207 28616
Austria 33621 67942 79638 73363 52904
Netherlands 20538 41591 36859 5487 −68668
United Kingdom 99342 154264 126052 19552 −173353
Ireland 3790 6811 4027 −5033 −24189
Poland 53818 67782 −81882 −389582 −853919
Germany 2866 −52828 −190275 −425185 −736324
France 39070 −67440 −517330 −1431800 −2707280
Base year = 2005.
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37,428 cases of the 4 smoking related diseases (taken to-
gether), a reduction in deaths from these diseases of
19,260 and a saving in health service costs attributable
to these diseases of €603.7 million. Figures for a 35% re-
duction are 440,648 fewer cases, 227,933 fewer deaths
and €7.1 billion saving in health service costs.
The effects of reduced smoking on overall health care
costs i.e. accounting for the long term health care costs
of an increase in the elderly population are shown in
Table 3. All countries show overall cost savings in the
short term with variable peaks (shown in bold). By 2030,
savings become negative in all countries apart from
Romania, Switzerland, Portugal and Austria due to the
cost of caring for greater number of older people.
Discussion
The PREVENT model predicts important reductions in
smoking related disease incidence and mortality and in
the health care costs of treating people with these dis-
eases across all 10 European countries following reduc-
tions in smoking of 3%, 15% or 35%. These reductions in
smoking are based on UK studies and clearly cessation
rates may vary between countries, they illustrate differ-
ences in the order of magnitude and in the timing of ef-
fects which can have important messages for national
health policies.
For a number of reasons, these total identified benefits
should be regarded as minima. Firstly, they relate to only
4 diseases and it has long been known that smoking in-
creases the risks of many other diseases (e.g. cataracts),
increases other risks (e.g. hip fractures) and inhibits re-
covery from non-smoking related illness (longer post
surgery recovery times). It is the cause of illness in non-
smokers who are exposed to second-hand smoke (pas-
sive smoking) and has long been known to lead to
higher levels of low birth rate babies in women who
smoke when pregnant. (See [16] for summary of effects
of smoking).
Reduced smoking can also lead to non-health benefits
particularly in terms of productivity gains to the econ-
omy. Workers who smoke have higher rates of sickness
absence from work than do non-smokers [17] which was
estimated to be responsible for 50 million lost working
days per year in the UK [18]. In Scotland alone, the total
annual costs due to such additional sickness absence
from work by smokers has been estimated at £40 million
(€47.2 million) [19]. In addition there are other benefits
of reduced smoking such as fewer fires. It has been esti-
mated that 10% of all fires in the UK are due to ciga-
rettes and a further 9% to use of matches [20].
Reductions in smoking related mortality, however,
mean more people living to old age which has implica-
tions for long term health care costs. The model predictsinitial overall health care savings in all countries which
reach a peak and then decline, becoming negative in six
of the ten modelled countries by the end of the modelled
period. Savings become negative when the population
structure contains a higher proportion of older people,
which will eventually occur in all ten cases but takes
more time in countries that start with a relatively young
population. Negative overall health care savings however,
cannot be interpreted as ‘negative’ results since they are
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which is the explicit objective of smoking cessation pol-
icies – as it is for all health care interventions. The deci-
sion to treat a patient suffering a myocardial infarction
(MI) is unlikely to include consideration of the fact that
saving his life means he will live to old age and become
a burden on the health service. There is no reason why
future health service costs should have any more influ-
ence on the decision to prevent the MI in the first place.
The fact that sufficient data to run the PREVENT
model were obtained from only 10 of 29 European coun-
tries does not mean that data for the remaining 19 do
not exist nor that the data provided for these 10 are ne-
cessarily as complete as might have been possible. Reli-
ance on local researchers in this many countries meant
that some variation in terms of the effort and rigor ap-
plied to obtaining data was inevitable. Despite this cav-
eat, results demonstrate that the quantity and quality of
data available for purposes of predictive modelling can
vary significantly across European countries. Neverthe-
less, deficiencies in the datasets were clearly often due to
those data not being collected and improvements in rou-
tine collection of data such as Burden of Disease data
and performing Costs of Illness studies would greatly as-
sist future smoking cessation research in Europe.
Differences in the predicted impact of reduced smoking
vary considerably between countries which has important
implications for evidence based policy. For example, while
the population of Germany is more than double that of
Poland (82.5 million versus 38.1 million) reductions in dis-
ease incidence following a 3% reduction in smoking in
2005 are considerably greater for Poland in the short term
(1069 versus 602 cases avoided in 2010) but in the long
term the situation is reversed (1,971 versus 2,333 cases
avoided in 2030). The overall health service cost saving for
both countries, however, peak and become negative fairly
quickly (Germany, peak in 2010 negative in 2015, Poland
peak in 2015 negative in 2020) as compared with say
Romania where the savings are still rising in 2030 and, due
to that being the last year modelled, will possibly continue
to rise even beyond that.
This study has demonstrated that there are dangers in
using evidence produced in one European country to in-
form smoking policy in another. Even neighbouring
countries that may superficially appear to be similar in
terms of some demographics have shown large dispar-
ities in the outputs generated in this study, demonstrat-
ing the need for careful analysis of accurate and
complete local datasets with a particular emphasis upon
collecting burden of disease and cost of illness data.
Limitations of the study
Considerable care needs to be taken in interpreting
these results which should be seen as illustrative. Thecompleteness of data to meet the requirements of the
PREVENT model varied considerably between countries
with fairly heroic assumptions being required in some
cases as shown in ‘Additional file 2’. Apart from the UK,
datasets for all countries required some adjustment or
imputation using data from another country. These varied
from minimal, for example in the case of the Netherlands
where all that was required was to apply age breakdowns
from France to Netherlands birth rates, to severe, for ex-
ample in the case of Austria, Portugal and Poland which
did not provide any cost figures and where Netherlands
costs were imputed. Clearly the accuracy of any prediction
varies with the number and severity of adjustments and
imputations required. The purpose of the study, however,
was to illustrate how the effects of reduced smoking can
differ between countries.
Results are reported as absolute values rather than as
rates. Clearly the implications of any given reduction in
the absolute number of new cases, deaths or health care
costs have to be interpreted locally with regard to the
size of the population. Converting values into rates,
however, requires predicting population growth rates in
addition to the predicting changes in the variables exam-
ined here. This would not have affected the main mes-
sages from the study.
Conclusions
In all countries modelled, healthcare costs initially fall be-
fore eventually rising as the population ages, however the
speed at which these changes occur varies greatly between
different countries. All countries show initial reductions in
health service costs as well as incidence and mortality for
the diseases combined, however the magnitude of the fig-
ures varies considerably between different countries, even
for countries of similar sized populations. Lack of data has
hindered the precision of results obtained and suitable
data should be routinely collected locally in order to ac-
curately model the effects of smoking cessation. With
more accurate data, the results which have been obtained
through the analysis in this study can be interpreted with
greater confidence and allow policy makers to make in-
formed choices about the costs and benefits of the imple-
mentation of smoking cessation programmes. It is clear
from this analysis that outcomes will vary according to
local factors and that it is not appropriate to assume that
uniform changes in smoking patterns will lead to identical
effects in different countries.
Additional files
Additional file 1: Sources of data used and assumptions: UK
dataset.
Additional file 2: Adjustments and imputations to European
country datasets.
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